# Cannabinoid Clinical Trials: CBD and Cortical Excitability Insights > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-antiseizure-pharmacokinetic-interaction-trial/ > **Published:** 2026-03-13T09:18:28-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:59:05-04:00 > **Clinical Summary:** Explore CBD antiseizure pharmacokinetic interaction and its role in clinical trials on cortical excitability and seizure management. --- #### Clinical Takeaway In a controlled crossover trial of healthy men, neither a low (30 mg) nor a high (700 mg) single dose of CBD directly altered cortical excitability compared to placebo. This suggests that CBD’s well-documented seizure-reducing effects in conditions like [Dravet syndrome](https://cedclinic.com/cannabidiol-for-epilepsy-treatment-rare-forms/) and Lennox-Gastaut syndrome may depend primarily on its pharmacokinetic interaction with clobazam rather than on any intrinsic action on brain excitability. Clinicians should recognize that CBD alone, at least as a single dose, may not carry independent antiseizure activity in otherwise healthy nervous systems. ### #10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial. **Citation:** Gorbenko Andriy A et al. *Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.* [Clinical pharmacology](https://cedclinic.com/temporary-placement-bromazolam-schedule-i/) and therapeutics. 2026. PMID: 40836528. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Cannabidiol  |  **CED Score:** 11 Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0 Why This Matters This study clarifies that CBD’s clinical efficacy in seizure disorders may depend primarily on drug-drug interactions rather than direct effects on neuronal excitability, which has important implications for predicting efficacy when CBD is used as monotherapy or with different ASM combinations. Understanding CBD’s mechanism of action is critical for optimizing seizure management strategies and identifying patients most likely to benefit from CBD-based treatments. These findings suggest that clinicians should carefully consider concomitant medications when prescribing CBD, as its therapeutic benefit may not translate reliably across different drug regimens. **Abstract:** Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with [Dravet syndrome](https://cedclinic.com/cannabidiol-for-epilepsy-treatment-rare-forms/), Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam. Clinical Perspective This well-designed crossover study provides valuable mechanistic insight by demonstrating that CBD’s seizure-reducing effects in approved indications likely stem from drug-drug interactions rather than direct effects on cortical excitability, which challenges assumptions about how this medication actually works at the neurobiological level. The finding is particularly relevant for clinicians prescribing CBD as adjunctive therapy, since it suggests that efficacy in conditions like Dravet and Lennox-Gastaut syndromes may depend critically on concurrent medications like clobazam, and that CBD’s role may be less about independent anti-seizure activity and more about pharmacokinetic modulation of other agents. However, we should note that a single trial examining cortical excitability in healthy or limited populations may not fully capture CBD’s effects in complex polypharmacy scenarios or in patients with different seizure etiologies, and the absence of direct cortical effects does not necessarily exclude other relevant mechanisms of action. Clinically, this research reinforces the importance  |   |  Further Reading Cannabis Policy Wire[Policy Watch: 25 Regulatory Updates — March 12, 2026](https://cedclinic.com/dea-scheduling-synthetic-drugs-march-12-2026/) Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40836528/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746520/)[DOI ↗](https://doi.org/10.1002/cpt.70038) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabidiol & Its Anti-Epileptic Properties: Clinical Trial Findings](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Review clinical trial data on cannabidiol’s anti-epileptic properties and its effects on seizure management. [Read More](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) [Cannabidiol Effects on Cortical Excitability: Evidence from a Randomized, Double-Blind, Placebo-Controlled Study](https://cedclinic.com/cbd-anti-seizure-activity-cortical-excitability-trial/) Explore detailed evidence from a [randomized trial](https://cedclinic.com/cannabis-cannabinoids-therapeutic-applications-review/) assessing cannabidiol’s impact on cortical excitability. [Explore Study](https://cedclinic.com/cbd-anti-seizure-activity-cortical-excitability-trial/) [Cannabidiol & Cortical Excitability: Clinical Trial Results](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Analyze [clinical trial results](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) focusing on cannabidiol’s role in modulating cortical excitability. [Learn More](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoid%20Clinical%20Trials%3A%20CBD%20and%20Cortical%20Excitability%20Insights&url=https%3A%2F%2Fcedclinic.com%2Fcbd-antiseizure-pharmacokinetic-interaction-trial%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcbd-antiseizure-pharmacokinetic-interaction-trial%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoid%20Clinical%20Trials%3A%20CBD%20and%20Cortical%20Excitability%20Insights%20https%3A%2F%2Fcedclinic.com%2Fcbd-antiseizure-pharmacokinetic-interaction-trial%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).